News
First Drug For Acid Sphingomyelinase Loss Approved By FDA
For intravenous infusion in paediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disorder that results in early death, the U.S. Food and Drug Administration has approved Xenpozyme (Olipudase alfa). Xenpozyme is the first drug that...
News
What Is Monkeypox, and Should You Be Worried?
Yes! We all should be. This terminal illness is caused by a virus located in tropical Africa. Despite its name, “Monkeypox,” monkeypox is spread by rodents such as rats, squirrels, and mice rather than ill monkeys. The virus is...
Drug Research
Non-Viral CRISPR May Potentially Boost Cell And Gene Therapy
A new variation of the CRISPR-Cas9 gene editing system, according to researchers from the Gladstone Institutes and University of California San Francisco (UCSF), enables the introduction of particularly long DNA sequences to specific locations in the genomes of cells...
Drug Research
Moderna Sues Pfizer, BioNTech Over mRNA COVID-19 Vaccines
According to complaints filed by Moderna, Pfizer and BioNTech's COVID-19 vaccine Comirnaty® violates patents the company filed between 2010 and 2016 that protect its core messenger RNA (mRNA) technology.
Both the Regional Court of Düsseldorf in Germany and the United...
Drug Research
Formulation Development Offshore Market To Be $60bn By 2030
A recent study predicts that the size of the global formulation development outsourcing market will increase from its value of $35.1 billion in 2022 to $61.4 billion by 2030, growing at a CAGR of 7.2%.
The researchers discovered that the...
News
By 2026, Pharma Contract Manufacturing To Be Worth $130bn
The global pharmaceutical contract manufacturing market is anticipated to reach $130.2 billion by 2026 as a result of increasing demand for pharmaceuticals, particularly in developing economies. In 2020, the market was estimated to be worth $100 billion.
Market research indicates...
News
Leanings In The Biopharma Contract Manufacturing For 2022
A recent survey found that 86.9% of biopharmaceutical businesses outsource at least a portion of their operations, which has contributed to the $14 billion market for biopharmaceutical contract manufacturing.
Over the next ten years, the investigators predict a very bright...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read